Publication:
Impact of prognostic nutritional index on survival in recurrent glioblastoma

Simple item page
dc.contributor.authorsAlan, Ozkan; Telli, Tugba Akin; Basoglu, Tugba; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Sakar, Mustafa; Bozkurt, Suheyla; Atasoy, Beste Melek; Dane, Faysal; Ziyal, Mustafa Ibrahim; Yumuk, Perran Fulden
dc.date.accessioned2022-04-25T00:12:13Z
dc.date.available2022-04-25T00:12:13Z
dc.date.issued2022
dc.description.abstractBackground: Primary brain tumors are relatively rare malignancy, with high-grade gliomas (glioblastoma multiforme and anaplastic gliomas) are the most common types. We aimed to evaluate the prognostic value of Prognostic Nutritional Index (PNI), which is calculated by lymphocyte count and albumin, in recurrent glioblastoma patients treated with systemic treatment. Methods: Data of 64 patients with recurrent glioblastoma who received systemic treatment and followed in our clinic between 2012 and 2018 was retrospectively collected and analyzed. PNI was calculated as: [(10 x serum albumin (g/dL)) + (0.005 x total lymphocyte count)]. Patients were categorized according to the median PNI value. We investigated the prognostic role of PNI groups, and survival outcomes. Results: Median value of PNI was 45.7, and median follow-up duration was 9 months (1-68 months). Median overall survival (OS) was 7.9 months (95%CI: 5.5-10.4). Median OS was significantly longer in patients with PNI > 45.7 compared to patients with PNI <= 45.7 (13.9 months (95%CI: 10.5-17.4), and 4.6 months (95%CI: 2.5-6.8), p < 0.001, respectively). In multivariate analysis, PNI was found to be an independent prognostic factor for OS [HR:0.41 (95%CI:0.22-0.74), p = 0.03)]. Conclusion: In our study, the PNI was found to be an independent prognostic biomarker in patients with recurrent glioblastoma, but further prospective trials are necessary to validate its prognostic role. (C) 2020 Sociedad Espanola de Neurocirugi acute accent a. Published by Elsevier Espana, S.L.U. All rights reserved.
dc.identifier.doi10.1016/j.neucir.2020.11.005
dc.identifier.eissn2340-6305
dc.identifier.issn1130-1473
dc.identifier.pubmed33454185
dc.identifier.urihttps://hdl.handle.net/11424/264043
dc.identifier.wosWOS:000740667000003
dc.languageeng
dc.publisherELSEVIER ESPANA SLU
dc.relation.ispartofNEUROCIRUGIA
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGlioblastoma
dc.subjectPrognostic nutritional index
dc.subjectOverall survival
dc.subjectInflammatory-based indices
dc.subjectSystemic treatment
dc.subjectLYMPHOCYTE RATIO
dc.subjectSERUM-ALBUMIN
dc.subjectPREDICTOR
dc.subjectCANCER
dc.subjectINFLAMMATION
dc.subjectNEUTROPHIL
dc.subjectCOHORT
dc.titleImpact of prognostic nutritional index on survival in recurrent glioblastoma
dc.typearticle
dspace.entity.typePublication
local.avesis.idda3536b2-d571-4c2f-9312-f50d6390fc12
local.import.packageSS39
local.indexed.atWOS
local.journal.numberofpages7
oaire.citation.endPage21
oaire.citation.issue1
oaire.citation.startPage15
oaire.citation.titleNEUROCIRUGIA
oaire.citation.volume33

Files

Collections

Research Outputs